Skin Vaccination Summit

28-30 March 2023, Royal College of Physicians of Edinburgh, Edinburgh, Scotland, UK

Recognition of the skin by vaccinologists as an ideal anatomical target has gathered momentum in the past decade. The premise that the dense population of APCs can be targeted, stimulated and loaded with antigens to induce robust immune responses and result in more efficacious vaccines has stimulated many efforts to understand skin physiology, the skin immune system antigen presenting cells, effector responses and modes of immune stimulation and delivery formats. The field is ripe to have broad interchange on relevant related disciplines to focus both research and development efforts on more effective and informative directions. With several products in late stage development and a newly licensed delivery device, a timely multi disciplinary interchange is greatly needed to help set the stage for progress that can lead to capitalizing on the immunopotency of the skin to bring about better human health.

The fifth SKIN VACCINATION SUMMIT – SVS 2023 will again offer an international forum for researchers, both academic and industrial, plus regulators and skin delivery technologists to meet and discuss the current developments and future direction and technology trends in the dynamic field of skin mediated vaccination.

The SVS 2023 meeting will comprise keynote presentations and special sessions and in addition the SVS 2023 organisers invite oral and poster abstract submissions to be considered for inclusion in the meeting schedule.

Mark Kendall (The Australian National University, Canberra, ACT, Australia)
Richard Compans (Emory University, Atlanta, Georgia, USA)
Behazine Combadiere (INSERM, Paris, France)
Yotam Levin (NanoPass Technologies Ltd, Rehovot, Israel)
Mark Prausnitz (Georgia Institute of Technology, Atlanta, USA)
Ryan Donnelly (Queen’s University Belfast, Northern Ireland, UK)
Terry L. Bowersock (Zoetis Inc., Kalamazoo, Michigan, USA)
Michael Royals (Independent Consultant, Denver, Colorado, USA)
Derek O’Hagan (GSK, Cambridge, Massachusetts, USA)
Steve Reed (IDRI, Seattle, Washington, USA)
Anne Moore (University of Cork, Cork, Ireland)
Marcel B.M. Teunissen (University of Amsterdam, Amsterdam, The Netherlands)
Izzy Tsals (SID Technologies LLC, Newtown, Pennsylvania, USA)
Laurent-Dominique Piveteau (Debiotech SA, Lausanne, Switzerland)
Bobby Singh (Corium International, Menlo Park, California, USA)
Erin Spiegel (Pharmajet, Golden, Colorado, USA)
Claus-Michael Lehr (Helmholtz Center for Infection Research (HZI), Saarland University, Saarbrucken, Germany)
Esther de Jong (University of Amsterdam, Amsterdam, The Netherlands)
Grace Macklin (WHO, Geneva, Switzerland)
Maria G. Isaguliants (Karolinska Institute, Stockholm, Sweden)
Markus Clemenz (Verapido Medical GmbH, Villingen-Schwenningen, Germany)
Koen van der Maaden (Leiden/Amsterdam Center for Drug Research, The Netherlands)
Andrey V. Romanyuk (Georgia Institute of Technology, Atlanta, Georgia, USA)

  • Layers and cells – considerable new data and debate on the skin APCs, their roles in immunity and there relevance to antigen presentation – Special session on Dendritic Cells.
  • Principles of Stratum Corneum Disruption – to immunize one has to access the living skin, so there are many techniques under development to do this – physics and physiology as it related to SC disruption/penetration.
  • Techniques for SC Disruption/Penetration: Methods and Madness (microneedles, microprojections, dissolvable needle approaches, ID, Patches – size) – Use, cost and commercialisation.
  • Techniques for ID injection – New methods and field experience with novel skin vaccines dermal delivery of DNA vaccines.
  • Skin vaccination – mechanistic interpretations (antigen trafficking across skin) – Reactivity issues (adjuvants and repeated dosing).
  • Animals and in vitro models for skin delivery – active field, most everyone working in the field needs to upgrade their approach – toxicology.
  • Clinical Evidence for the immunological advantage of skin targeting – Clinical data only, many studies and investigators… ID mainly but several techniques.
  • Immunological Rationale for skin targeting – effector results, T cells, humoral and mucosal antibodies – preclinical evidence for the immunological advantage of skin targeting – local reactions.
  • Adjuvants for skin targeting – there are many cancer trials using skin and delivery adjuvants to the skin – there are many adjuvants in development to target skin – tox/reactogenicity requirements for skin targeting.
  • Public health aspects of skin immunization – improving access to vaccines – stabilization technologies to avoid the cold chain – prospects for self-administered vaccines – issues for mass vaccination.
  • Prophylactic vs therapeutic vaccines and skin delivery.
  • Size of patches or delivery systems – multivalent versus monovalent vaccine applications and live versus inactivated vaccines.
  • Formulation matters · Immune medium (cytokine production by DCs, adipocytes, fibroblasts etc) · Immune suppression of skin constituents · In vitro skin models · Regulatory planning for ID vaccines.